The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Overview of attention for article published in British Journal of Cancer, December 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (74th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

patent: 1 patent

Citations

dimensions_citation: 49 Dimensions

Readers on

mendeley: 71 Mendeley

Summary X Patents Dimensions citations

So far, Dimensions has found 49 publications that cite this research output.

49

The most recent citing publications are shown below. View all 49 publications that cite this research output on Dimensions.

The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance

Article in Cancer Research (September 2023)

Survival impact of fulvestrant-based combination therapies in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer with liver metastasis: a case-control study

Preprint in Research Square (August 2023)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models

Article in npj Breast Cancer (August 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.